doi: 10.1128/AAC.32.2.268.
In vitro susceptibilities of common pediatric pathogens to LY163892
Affiliations
- PMID: 3129989
- PMCID: PMC172150
- DOI: 10.1128/AAC.32.2.268
Item in Clipboard
In vitro susceptibilities of common pediatric pathogens to LY163892
Antimicrob Agents Chemother.
1988 Feb.
Abstract
LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid. It has greater stability than cefaclor and greater activity against beta-lactamase-producing Haemophilus influenzae and Escherichia coli. LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens.
Similar articles
-
Comparative in-vitro activity of a new oral carbacephem, LY163892.J Antimicrob Chemother. 1988 Oct;22(4):445-56. doi: 10.1093/jac/22.4.445. J Antimicrob Chemother. 1988. PMID: 3060458
-
In vitro activity of BAY v 3522, a new oral cephalosporin.Antimicrob Agents Chemother. 1990 Sep;34(9):1855-7. doi: 10.1128/AAC.34.9.1855. Antimicrob Agents Chemother. 1990. PMID: 2126697 Free PMC article.
-
In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis.Antimicrob Agents Chemother. 1991 Jul;35(7):1504-7. doi: 10.1128/AAC.35.7.1504. Antimicrob Agents Chemother. 1991. PMID: 1929318 Free PMC article.
-
Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):5S-12S. doi: 10.1016/j.diagmicrobio.2006.12.014. Epub 2007 Feb 9. Diagn Microbiol Infect Dis. 2007. PMID: 17292577 Review.
-
[Respiratory tract infections: how frequent is antibiotic resistance? In vitro activity of older and recent antibiotics against the significant pathogens].Fortschr Med. 1994 Nov 30;112(33):485-8. Fortschr Med. 1994. PMID: 7843673 Review. German.
Cited by
-
Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.Infection. 1992 May-Jun;20(3):176-82. doi: 10.1007/BF01704619. Infection. 1992. PMID: 1463527 Clinical Trial.
-
Loracarbef concentrations in middle ear fluid.Antimicrob Agents Chemother. 1990 Oct;34(10):2030-1. doi: 10.1128/AAC.34.10.2030. Antimicrob Agents Chemother. 1990. PMID: 2291672 Free PMC article.
-
Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.Antimicrob Agents Chemother. 1991 May;35(5):967-71. doi: 10.1128/AAC.35.5.967. Antimicrob Agents Chemother. 1991. PMID: 1854178 Free PMC article. Clinical Trial.
-
Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.Infection. 1992 Sep-Oct;20(5):301-8. doi: 10.1007/BF01710806. Infection. 1992. PMID: 1428189 Clinical Trial.
-
Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.Drugs. 1993 May;45(5):716-36. doi: 10.2165/00003495-199345050-00008. Drugs. 1993. PMID: 7686466 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
